Cantor Fitzgerald Initiates Coverage On Ovid Therapeutics with Overweight Rating

Cantor Fitzgerald analyst Imogen Mansfield has initiated coverage on Ovid Therapeutics (NASDAQ: OVID) with an Overweight rating. This marks a significant endorsement for the company as it seeks to attract investor interest.